PCR-based detection of minimal residual disease (MRD) in children with precursor B cell acute lymphoblastic leukemia (pre-B ALL) by amplification of clone-specific antigen gene rearrangements has been labor-intensive. In this study we present a simpler, yet accurate, method to assess and quantitate MRD in pediatric pre-B ALL that utilizes these markers. . The method is demonstrated on 18 patients whose marrows were prospectively analyzed during therapy. We conclude this methodology is useful in the quick and accurate assessment of MRD in children with pre-B ALL, and could be applied to other DNA quantitation assays.
Introduction
Various methodologies have been developed to monitor minimal residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL), each with its own set of advantages and disadvantages. For instance, flow cytometry is useful for the immunological detection of leukemic cells that carry a unique pattern of surface markers, and has a sensitivity of 10 −4 , but is useful in only 57% of all cases. 1 Fluorescence in situ hybridization (FISH) is useful in leukemias with abnormal karyotypes, suitable for use with archival tissue sections, and allows for further analysis of the positive cells; however, at best the sensitivity approaches only 10 . 2 PCR amplification of chromosomal translocations allows examination of a cancer-specific marker, but can only be utilized in approximately 37% of cases 3, 4 and usually requires the availability of mRNA. Conversely, PCR amplification and detection of clonal IgH and TcR rearrangements can be used in about 80% of patients 5 and has a sensitivity as high as 1 × 10 −4 to 1 × 10 −6 . Its disadvantages traditionally include labor-intensive methodologies related to individualizing each assay for the clone-specific gene rearrangement, and laborious quantitation techniques.
A consequence of the difficulties associated with MRD assessment is the lack of unity in the prognostic significance thereof. Cavé et al, 5 as part of a recent multi-center study, concluded that the presence of residual leukemia at the end of induction therapy is a powerful prognostic factor in childhood ALL. Although there is a general consensus that a persistent or increasing level of leukemic cells during therapy has been associated with a poor prognosis, [6] [7] [8] [9] [10] some evidence suggests that low levels of persistent leukemic cells after therapy may be compatible with long-term survival 11 and that the absence of detectable leukemic cells may not guarantee leukemia-free survival. 12 These conflicting data may reflect smallscale studies, retrospective analyses, heterogeneity of treatment protocols, and/or varying detection methodologies. Thus, there is a clear need for a simplified, yet accurate and reproducible, assay to enable large-scale prospective studies to be more readily transferable to clinical trials.
We have developed a simple and reproducible quantification method utilizing a single-round PCR assay, mediated by new primer design guidelines, that minimizes potential contamination and optimizes sensitivity. The results of a prospective study is presented in which MRD levels were monitored in the remission bone marrow (BM) samples of 18 children.
Materials and methods

Patients and sample processing
BM samples were obtained at diagnosis or relapse from 59 children with pre-B ALL, and whenever possible, at the end of induction and every 4-6 months thereafter. Forty-seven of these patients harbored detectable clonal rearrangements and form the basis for this report. Aspirates performed prior to July 1996 were stored either as smears on microscope slides or as frozen DNA extracted from 1-3 ml samples. After July 1996, fresh BM aspirates were obtained. Aspirates were performed at the Westchester Medical Center and New York Medical College. Diagnosis was based on FAB classification and immunophenotyping; complete remission was defined as less than 5% lymphoblasts detectable by light microscopy. Informed consent was obtained from the parents or legal guardians of the patients, and the study was approved by the Institutional Review Board of New York Medical College.
Mononuclear cells were isolated using Histopaque-1077 (Sigma, St Louis, MO, USA), and DNA was extracted by standard procedures. Briefly, cells were lysed in lysis buffer and proteinase K, followed by phenol/chloroform extraction and ethanol precipitation. DNA pellets were resuspended in sterile water and stored at −20°C until use. Quantification of DNA was achieved by spectrophotometric analysis using the Gene-Quant RNA/DNA Calculator (Pharmacia Biotech, Piscataway, NJ, USA). DNA was extracted from archival microscope slides of diagnostic bone marrow aspirates when fresh cells were unavailable. Cells were removed from the slides by a filter paper moistened with lysis buffer, transferred to tubes containing lysis buffer and proteinase K, and DNA was extracted as above.
Characterization of diagnostic IgH and TcR gene rearrangements
DNA samples extracted from diagnostic bone marrow mononuclear cells were screened by PCR for clonal IgH gene rearrangements using consensus primers Vu and Ju, V␦2-D␦3 gene rearrangements using consensus primers V␦2 and D␦3, and D␦2-D␦3 gene rearrangements using consensus primers D␦2 and D␦3. The ␤-globin gene was amplified using universal primers HBG7-F and HBG7-R to confirm DNA integrity. Sequences of oligonucleotide primers are listed in Table 1 . Amplification was performed by an initial denaturation at 94°C, followed by 35 cycles at 94°C, 55°C, and 72°C, each for 30 s, and a final extension at 72°C for 7 min in a thermocycler (PC 200, MJ Research, Watertown, MA, USA). Reaction mixtures contained 1 g DNA, 300 ng of each oligonucleotide primer, 1 × reaction buffer (Perkin Elmer-Cetus, Foster City, CA, USA), 2.5 U Amplitaq DNA polymerase (Perkin Elmer-Cetus), and 1.5 mm MgCl 2 . Synthetic oligonucleotide primers were synthesized by Integrated DNA Technologies (Coralville, IA, USA). Precautions against cross-contamination of amplified material were taken according to the recommendations of Kwok and Higuchi. 13 PCR products were separated on ethidium bromide-stained 4% Nusieve (FMC BioProducts, Rockland, ME, USA) agarose gels. Positive bands were excised and products were eluted using Microcon 30 filters (Amicon, Beverly, MA, USA) and PCR products were directly sequenced by services of the DNA Sequence Facility of The Wistar Institute Cancer Center (Philadelphia, PA, USA). Sequences were analyzed for rearrangements of the V, D, and J segments using software provided by The Wistar Institute Cancer Center Bioinformatics Facility. 
Clone-specific single-round PCR
For every remission bone marrow DNA sample, a 10-replicate PCR set was tested. Diagnostic DNA was amplified as a positive control, and negative controls included ultra-filtered sterile water and DNA extracted from normal peripheral blood mononuclear (NPB) cells. The ␤-globin gene was simultaneously tested in a different tube with the appropriate controls to confirm DNA integrity. For patients diagnosed after March 1998, a 1 × 10 −4 dilution of diagnostic DNA into normal human DNA (10 template copies) was used as a control for sensitivity. Each PCR mixture included 1 g genomic DNA (except for the water controls), 300 ng each universal and clone-specific primer as explained above, 10 mm Tris-HCl, pH 8.3, 50 mm KCl, and 200 m each dNTP (Perkin ElmerCetus), in a 100 l reaction volume. Optimal MgCl 2 concen-tration (between 0.8 and 1.2 mm) was empirically determined for each clone such that the NPB DNA control was negative and the diagnostic DNA control yielded a product at the expected molecular weight. After a 5-min incubation of the mixture at 80°C, 2.5 U of AmpliTaq polymerase (Perkin ElmerCetus) were added, followed by a denaturation step of 94°C for 3 min. Cycles consisted of denaturation at 94°C for 45 s, annealing at 66°C for 45 s and extension at 72°C for 30 s, for a total of 45 cycles, which was performed in a thermocycler (Perkin-Elmer-Cetus, Model 480). The final extension step was increased to 7 min. To minimize the risk of contamination, the DNA sample for the positive control was handled only after the addition of AmpliTaq polymerase to all the samples.
Amplified products (10 l) were separated by electrophoresis on pre-cast 10% polyacrylamide gels (Owl Separation Systems, Portsmouth, NH, USA), and stained with SYBRGreen I nucleic acid stain (FMC BioProducts). The wet gels were scanned at 750 V in a FluorImager 595 with a 530DF30 filter and analyzed using ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA). When all 10 of the PCR replicates were positive, genomic DNA was serially diluted into normal human DNA (described below). Ten-replicate PCRs with the controls stated above were performed on these dilutions in tandem, starting with the most concentrated, until two to eight of the 10 replicates were positive. Quantitation was achieved by interpolation to the model curve described below.
DNA sequencing of positive remission samples
In order to confirm that the positive remission BM samples were not artifacts, the PCR products from all samples were sequenced. For every sample that demonstrated two or more positive reactions in the 10 replicate assay, two samples were processed for sequencing. In cases where only one of the replicates was positive, only the one was sequenced. For the replicates that were chosen for sequencing, the intensity of the band from the ImageQuant (Molecular Dynamics) imaging was qualitatively assigned a number from 0.05 to 3, depending on the intensity of the band, where 3 was the darkest. Samples designated as 2 or lower were subjected to additional rounds of amplification under the same conditions, but spiked with an additional 1.25 U Amplitaq polymerase (Perkin-Elmer-Cetus). Ninety microliters of the PCR products were concentrated and run on agarose gels, the bands were eluted and sequenced as described above for diagnostic and relapse samples. Sequencing was performed in only one direction, using one universal primer.
Optimization of single-round PCR sensitivity
Preliminary work was performed on a 5 × 10 −5 dilution of diagnostic DNA into a background of normal human DNA. Ten-replicate PCR sets and appropriate controls were performed as discussed above, except either 40 or 45 PCR cycles were completed. In order to compare the sensitivity of detection, the amplified products were run either on 10% PAGE, stained with SYBRGreen I nucleic acid gel stain (FMC Bioproducts), which has a sensitivity 100× that of ethidium bromide (SYBRGreen package insert), and scanned in the FluorImager as above, or run on ethidium bromide-stained 4% Nusieve gels and photographed under UV illumination.
Development of model curve
Diagnostic DNA samples that had at least 90% blasts and were monoclonal as evidenced by amplification of the IgH and TcR V␦2-D␦3 and D␦2-D␦3 gene rearrangements were used for the quantitation analysis. To avoid using potentially degraded DNA, six patients diagnosed within 1 year preceding the analysis were used for generation of these data (four with an IgH gene rearrangement, one with a V␦2-D␦3 gene rearrangement, and one with a D␦2-D␦3 gene rearrangement). DNA dilutions were performed as follows. A stock solution of 100 ng/l diagnostic genomic DNA was incubated at 95°C for 1 min, vortexed, centrifuged for 30 s, vortexed again, and allowed to cool to room temperature. Twenty microliters of this sample was transferred to 180 l of human DNA (100 ng/l) that did not contain the target sequence, the mixture was vortexed, and the steps were repeated for each dilution except either 1/10, 1/5, or 1/2 dilutions were performed. To minimize errors, the smallest volume used was 10 l. A 10-replicate PCR set was completed for each dilution using the procedure above for amplification of patient-specific IgH and TcR gene rearrangements. The Von Krogh model and the Poisson equation were fit to the model of the composite data from the 10-replicate PCR sets for the six patients. For the Von Krogh model, the non-linear regression model was estimated to produce model constants and a measure of the fit of the data.
Comparison of single-round PCR to hemi-nested PCR
To assess the sensitivity of the clone-specific single round PCR assay to that of a hemi-nested PCR, we performed 10-replicate PCRs using both methodologies on five diagnostic clones (one V␦2-D␦3, one D␦2-D␦3, and three IgH) in three patients. Both IgH gene rearrangements from one patient and the V␦2-D␦3 and D␦2-D␦3 from another patient were included to assess intra-specimen variability. A 1 × 10 −5 dilution of diagnostic DNA from each patient in human DNA was performed as described above. The first round of hemi-nested PCR was performed under the same conditions as described for characterizing the diagnostic clones, except for only 25 cycles, using the appropriate universal primers. A total of 10 replicates of the 1 × 10 −5 dilution were performed for each clone and diagnostic DNA (1 × 10 −2 dilution), NPB DNA and ultra-filtered sterile water were included as controls. PCR products were diluted 1:100 in sterile water and 1 l of each dilution was added to a second round of PCR. Hemi-nested PCR conditions were as described above in the clone-specific single-round PCR section. At a different time, the 1 × 10 −5 diagnostic DNA dilutions of these clones were subjected to a 10-replicate clone-specific, single-round PCR as described above. All PCR products were analyzed by running on 10% PAGE, followed by SYBRGreen staining, then scanning and image analysis using the FluorImager as described above. Results were analyzed using a paired-samples t-test. 
Results
Characterization of diagnostic clone-specific antigen gene rearrangements
Optimization of sensitivity of detection
Preliminary optimization of sensitivity was performed on a 5 × 10 −5 dilution of DNA extracted from a diagnostic DNA sample as explained in the Methods section. Figure 2a shows that the 45-cycle PCR products run on an agarose gel, stained with ethidium bromide, and photographed under UV illumination allowed the detection of expected products in two out of the 10 PCRs, consistent with the sigmoid curve generated by the composite data of Ouspenskaia et al 14 and suggesting a sensitivity comparable to that reported by those authors. PAGE separation of a second 10 l of the same PCR products stained with SYBRGreen, and scanned using the FlourImager 595 revealed a positive reaction in nine of the 10 samples, and an absence of nonspecific bands in the sample and negative controls (Figure 2b) , indicating a higher sensitivity of detection with the fluorescence staining. The positive control yielded not only the 76 bp expected product, but also a band at about 150 bp. The template for the positive control for the preliminary work was a dilution of PCR products of the diagnostic clone amplified by the Vu and Ju primers. Analysis of the PCR products after 40 cycles by SYBRGreen-Fluorlmager detection (Figure 2c ) revealed a positive reaction in only four of the 10 PCRs, indicating that at least 45 cycles are necessary for efficient detection of products from a single DNA template copy in this system. To confirm that staining of the PCR products with SYBRGreen significantly improved the detection sensitivity over that of ethidium bromide, the comparison of the two stains was repeated two additional times. The 10-replicate PCR products of a 1 × 10 −5 dilution of both the IgH and V␦2-D␦3 clones from the diagnostic DNA from a different patient were stained in parallel with SYBRGreen and ethidium bromide, then analyzed under UV illumination and FluorImager scanning, respectively. For the SYBRGreen stained products, six of the 10 positive reactions for each clone were positive; whereas none of 10 for the IgH and one of 10 for the V␦2-D␦3 ethidium bromide-stained products were positive (data not shown).
Generation of model curve
The composite results of 10-replicate PCRs from six patients with a single IgH or TcR gene rearrangement at diagnosis, after serial dilutions in human DNA, were used to plot the fraction of positive reactions as a function of the dilutions. The composite data produced a sigmoid curve. An asymptotic exponential response model of the Von Krogh form, F + = a (1-10 −bd ), 15 where F + is the fraction of positive samples and d is the dilution, was then fit to produce model coefficients. DNA sequences of clonal IgH and TcR gene rearrangements derived from the consensus PCR products of pre-B ALL diagnostic bone marrow aspirates. Locations of clone-specific primers used for quantitation of MRD are underlined. IgH primers are in the reverse orientation to amplify with the universal Va primer and TcR primers are in the forward orientation to amplify with the universal JD3-11 primer. The exception is clone BC13, for which the primer is in the reverse orientation to amplify with the universal V␦2MRD primer. For visual clarity, the N regions are in bold.
resenting the fraction of positive reactions as a function of the dilution of DNA is displayed in Figure 3 . As shown, the sensitivity of the single-round clone-specific PCR assay is 2 × 10 −6 , meaning that the lowest number of leukemia cells that can be detected is two, given that the total number of cells tested is 1 × 10 6 . The composite results were also fit to the Poisson equation (P = 0.37), but Poisson statistics could not explain the data, and further analysis using the Poisson equation was not pursued.
Using the Von Krogh model curve, quantitation of MRD in remission BM samples was achieved by interpolating to the model, blast concentration = [log 10 (1 − F + /a)b 
Amplification of diagnostic DNA from remaining patients
Application of this method to other diagnostic IgH, V␦2-D␦3, and D␦2-D␦3 gene rearrangements resulted in intense bands within the predicted region for 52 of 54 clonal IgH gene rearrangements and simultaneous absence of detectable PCR products in the negative controls. Figure 4 shows PCR products from a representative panel of clone-specific amplification of these diagnostic samples. Two sets of primers for the IgH gene rearrangement yielded one intense band at the predicted size and one fainter band (patients BC41D and BC39U). Sequencing analysis indicated that these secondary bands were products of a VH-VH gene replacement, most likely due to clonal evolution before diagnosis. Eight of the 10 primers for amplification of the TcR V␦2-D␦3 also revealed the expected PCR product with negligible background. One primer amplified DNA from the peripheral blood of a healthy donor; however, redesigning this oligonucleotide by moving it upstream 2 bp abrogated that amplification. Three primerdesign attempts to amplify the rearrangement from patient BC 13 failed due to non-specific amplification; however, designing the patient-specific primer in the reverse direction, and amplifying with an upstream universal primer (primer V␦2MRD, Table 1 ), allowed successful amplification. All three D␦2-D␦3 clone-specific oligonucleotides revealed the expected PCR products in the absence of background. In summary, 66 of 67 clonal-specific amplifications yielded successful results following the standard guidelines for primer design, and the remaining clone-specific amplification worked after a slight modification.
MRD detection and quantitation in a prospective study
Out of the 20 patients that were included in the 2-year prospective study, one or more clonal IgH or TcR gene rearrange- 
Figure 3
Model curve from PCR analysis on known concentrations of diagnostic DNA. DNA obtained at diagnosis from six patients were diluted in series of 1/10, 1/5, 1/2, then amplified in 10-replicate clonespecific PCR sets. Composite data was fit to a sigmoid curve of the asymptotic response form. Each point represents data from six patients and the curve was generated by non-linear regression modeling. ment was successfully characterized in 18, a rate consistent with previous reports. Seventeen of the 18 children who were followed are in clinical remission, as well as the two for whom a clonal gene rearrangement was not characterized at diagnosis. See Table 2 for quantitation results of the remission BM samples. Of the 13 patients for whom a sufficient marrow sample was available during the initial 2 months, eight were positive. Out of seven of these patients who were evaluated between 8 and 12 months, two were positive. For patient BC 39, whose IgH clones were positive at 1-2 months but became negative at 8-12 months, the D␦2-D␦3 clone was positive at 8-12 months, but not tested between 1-2 months due to insufficient DNA. Surprisingly, an overall trend of decreasing number of positive patients throughout the period of treatment was not observed, where two of three patients between 2-4 months, three of 10 between 4-8 months, five of 11 between 8-12 months, one of seven between 12-16 months, three of nine between 16-20 months, and one of six between 20-30 months were positive ( Table 2 ). The marrows in four patients became positive after being negative, but just at the threshold of detection, where accurate quantitation was not possible. Mean follow-up for these four patients, after becoming positive, is 7.5 months. Marrows from two of these patients have subsequently been negative. One patient's leukemia was refractory to treatment. PCR analysis for this patient at day 28 showed that the leukemic burden was 11% (10.3-11.7%), whereas the morphologic analysis was considered a CR.
Figure 4
Clone-specific PCR products from a representative panel of diagnostic samples. Diagnostic DNA was amplified using the appropriate consensus and clone-specific primers. PCR products were run on 10% PAGE, stained with SYBRGreen (FMC), and scanned with the FlourImager (Molecular Dynamics).
Table 2
Quantitation of residual leukemia cells using single-round, clone-specific PCR 
DNA sequencing of positive samples
A total of 25 samples from the 18 patients were positive during remission. In order to confirm that the positive results were due to true MRD and not the product of artifacts, these samples were sequenced. One sample, the 16 to 20 month marrow from patient BC 9 was not yet sequenced at the time of the report, and sequencing analysis failed in the most recent sample from this patient. The clone-specific PCR products from both samples of another patient, BC 2, were too short (44 bp) to draw any conclusions, as evidenced by the fact that the sequence generated consisted of the clone-specific primer and no N region. The remaining 21 samples were successfully sequenced, 17 of which were the same as that characterized at diagnosis. It is noteworthy that sequences from patients BC 4 (IgH), BC 6 (V␦2D␦3), and BC 39 (IgH U) were different from the diagnostic clone. More interestingly, the new clone identified from both positive remission marrow samples from patient BC 6 was the same.
Comparison of clone-specific, single-round PCR to hemi-nested PCR
The results from a heminested PCR were compared to those of the clone-specific, single-round PCR. A 10-replicate PCR assay using both approaches was performed on a 1 × 10 −5 dilution of diagnostic DNA/human DNA for five diagnostic clones in three patients. The results were analyzed using a paired-samples t-test. This analysis revealed there is no significant difference between the mean number of positive reactions observed in the two methodologies, t(5) = 0.56; P = 0.61. The fraction of positive reactions, sample means, and standard deviations are shown in Table 3 , which shows that the mean fraction of positive reactions in the single-round PCR approach is not significantly different than those in the heminested PCR approach. The hemi-nested PCR for the V␦2-D␦3 clone for patient 1 revealed 0 positive reactions, with no aberrant results in the positive and negative controls for the assay. To minimize the chance that this low reading was due to a random technical error, the dilution and 10-replicate hemi-nested PCR was repeated, which also resulted in 0 positive reactions.
Discussion
The most important step in attaining a reliable sensitivity of detection of MRD, utilizing the IgH and TcR gene rearrange- 5 demonstrated that the use of a competitive PCR approach, co-amplification with an internal standard, was useful in detecting residual cells in the bone marrow of children with ALL. However, the dot-blot radiolabeled probe hybridization methods used by these and previous investigators are labor-intensive. Dibenedetto et al 16 simplified MRD detection by using a fluorescent hemi-nested PCR approach that included a clone-specific primer in the second round of PCR, and demonstrated that it is comparable in sensitivity. However, this methodology favors carryover, essentially because it is virtually impossible to completely isolate the preand post-PCR areas. In addition, the aforementioned studies involved testing only one sample replicate, and due to potential tube-to-tube fluctuations, quantitation may not have been accurate. To compensate for these fluctuations, a quantitative, limiting-dilution, and the 10-replicate PCR assay was developed 17 then subsequently improved by Ouspenskaia et al. 14 However, a two-step PCR technique was utilized and because a higher and prolonged incidence of positive samples was reported, 11 the possibility of contamination from the second round of PCR should be considered.
A novel technique, the 'real-time' quantitative PCR (RQ-PCR) 17 has recently become available that semi-automates the conventional PCR methodology. In this assay, an internal fluorogenic probe specific for the amplicon is degraded, resulting in an increase of fluorescence emission as the number of cycles is increased. Post-PCR handling of the samples is not necessary because a fluorescence scanner provides the real-time detection of amplification. Several reports have demonstrated the usefulness of RQ-PCR in the quantitation of MRD, [18] [19] [20] and a combination of the guidelines for reproducibly designing clone-specific primers as presented here, with real-time detection, could prove useful.
The purpose of this project was two-fold. First, we set out to optimize the clone-specific primer designation process in order to avert a second round of PCR. Second, we wished to develop a standard model curve by amplifying serial dilutions of diagnostic DNA samples from which the level of MRD in follow-up samples could be calculated. Because we successfully obtained clone-specific PCR products in the absence of non-specific amplification for all 67 clones identified in 47 diagnostic samples, we conclude that this method is robust and reproducible. In addition, data from the quantitation of six diagnostic samples fit the asymptotic response model with a detection sensitivity of 2 × 10 −6 , which permitted an accurate quantitation of the MRD burden for patients during clinical remission.
Establishment of the model curve made it unnecessary to repeat the entire quantitation assay for each clone. Theoretically, a diagnostic sample could be diluted to 1 × 10 −5 and amplified in 10 replicate PCRs and if the fraction of positive reactions falls within the expected range, the overall sensitivity of the PCR using that set of primers would be confirmed. However, it may be necessary for each group of investigators to establish their own model. This method could be applied to patients with multiple clonal rearrangements at presentation, although with caution. Because the actual number of positive cells associated with each clone is unknown, initial assumptions are required about the efficiency of each set of primers. Assuming primer efficiency comparable to that reflected in the standard curve, these patients could be followed for MRD throughout treatment. Use of a specialized automated primer design software package (currently in development) would assure uniform efficiency, as well as help standardize the methodology. In addition, simultaneous amplification of a remission sample with a 1 × 1 −4 dilution of diagnostic DNA, which we have been doing for all patients diagnosed after March 1998 (data not shown), confirms the sensitivity of the assay on a daily basis.
The Von Krogh model provided a suitable fit of the data, whereas Poisson statistics failed to explain the asymptotic response curve generated by the data (P ϭ 0.37). This is consistent with the results of a previous report 14 and confirms that PCR quantitation assays require parameters not explained by simple Poisson statistics. The Von Krogh model is actually a generalized form of Poisson but is more functional because it contains constants that are essential in defining the parameters of the assay.
Because of the limited number of patients enrolled in the prospective study (n = 20) and the low frequency of relapse (n = 1), no clinical conclusions can be drawn. However, largescale trials have already established the validity of monitoring MRD throughout treatment. 5, 21 The purpose of this report is to demonstrate the simplicity, reproducibility and accuracy of the methodology. We sequenced the marrow samples that were positive during remission in an attempt to determine the specificity of the single-round PCR assay. However, it may not be practical, or necessary, to sequence all positive remission samples in a clinical trial. It is interesting that the sequencing analysis of the marrows of three of the four patients who became positive after being negative had clones different than that identified at diagnosis. One possible explanation is that these clones are the result of clonal evolution. We are currently investigating whether these new clones were present at diagnosis, but not expanded enough to be detectable by amplification with universal primers. Conversely, if these clones are the result of normal recombination in the B cells of these children, then the usefulness of utilizing the IgH and TcR as markers may be limited. In any event, it will be interesting to continue monitoring the level of MRD in these children to determine the significance of these new clones.
A limitation of the assay is the assumption that the DNA samples were uniformly intact and free of reaction inhibitors. Chemical modifications due to strand brakes, depurination, or formation of adducts may decrease the number of templates available for PCR, and varying degrees of contamination of the sample with heme or salts could result in a less amplifiable population, both of which could alter the estimation of the level of MRD. Internal standards were not included because competition of both products can lower the overall sensitivity of the PCR. 22 Uniform extraction procedures, prospective testing, and simultaneous amplification of the ␤-globin gene reduce the chances of false negatives that arise from excessive degradation and PCR inhibitors. However, when the DNA quality is uncertain, further analysis by performing a 10-replicate PCR of the ␤-globin gene on a dilution of the sample could elucidate its true amplifiability.
This simple and reproducible method to assess MRD levels can be readily applied to large prospective studies. Results can be obtained within 48 h after receipt of the bone marrow specimen. Hands-on processing of the sample involving DNA extraction, PCR setup, and post-PCR analysis, requires only about 4 h. Use of pre-cast gels is more efficient and cost-effective than self-prepared gels. Automated sequencing and computer software analysis of the VDJ segments simplifies generation of clonospecific primers. PCR setup time is reduced by use of a pre-made master mix, where only MgCl 2 , primers, and DNA are added. Finally, primers are designed to enable the use of the same PCR conditions for every antigen rearrangement, allowing for simultaneous testing of multiple samples. Thus, we conclude that our PCR-based method to detect and quantitative MRD is simple and suitable for largescale prospective monitoring.
